Although surgery, systemic chemotherapy, radiotherapy, immunotherapy, and targeted therapy have been widely used to treat GC (49, 50, 51), antitumor drugs targeting the upstream kinases of the RB-E2F pathway are currently only in clinical trials for GC, and there are no drugs directly targeting E2F that are currently in clinical trials (52). Here, RB1 is linked to gastric cancer.